Literature DB >> 31607054

[The mortality burden of influenza in China: a systematic review].

S Li1, S S Liu2, A Q Zhu3, J Z Cui3, Y Qin3, J D Zheng3, L Z Feng3, L P Wang3, Z J Li3.   

Abstract

Objective: To systematically review the mortality burden study of influenza in mainland China. Method: "influenza", "flu", "H1N1", "pandemic", "mortality", "death", "fatality", "burden", "China" and "Chinese" were used as keywords, and a systematic literature search was conducted to identify articles in three English databases (PubMed, Web of Science and Embase) and three Chinese database (CNKI, WanFang and VIP) during 1990-2018 (excluding Hong Kong, Macao and Taiwan). The language of literature was restricted to Chinese and English. The inclusion criteria were human-oriented researches with method based on population, and research indexes included mortality and excess mortality. The exclusion criteria were non-primary research materials, predictive research and research on the burden of avian influenza related deaths. A total of 17 literatures were included, and the basic information to descriptive characteristics, methodology of modeling and the corresponding results were extracted.
Results: All the 17 studies adopted indirect statistical models, with 14 of which adopted the regression model, and all the research index was excess mortality. All causes (16 studies), respiratory and circulatory diseases (14 studies) and pneumonia and influenza (10 studies) were the main causes of death associated with influenza. Influenza associated mortality burden in the elderly was higher, with the lowest excess mortality rates of all causes, respiratory and circulatory diseases, pneumonia and influenza being 49.57, 30.80 and 0.69 per 100 000 people, and the highest rates being 228.16, 170.20 and 30.35 per 100 000 people, respectively. In the non-elderly, the corresponding lowest rates were -0.27, -0.08 and 0.04 per 100 000 people respectively, and the highest rates were 3.63, 2.6 and 0.91 per 100 000 people, respectively. The influenza-related excess mortality was higher in the north, with a minimum of 7.8 per 100 000 and a maximum of 18.0 per 100 000, and slightly lower in the south, with a minimum of 6.11 per 100 000 and a maximum of 18.7 per 100 000. There were also differences in deaths caused by different influenza virus subtypes, with influenza A(H3N2) and influenza B virus possibly posing a heavier mortality burden. Conclusions: Studies on influenza mortality burden is mainly based on indirect model and urban level in China. The mortality burden of influenza in the elderly, the northern and subtype A(H3N2) and B were more severe.

Entities:  

Keywords:  Death; Influenza, human; Mortality burden; Systematic Reviews

Mesh:

Year:  2019        PMID: 31607054     DOI: 10.3760/cma.j.issn.0253-9624.2019.10.018

Source DB:  PubMed          Journal:  Zhonghua Yu Fang Yi Xue Za Zhi        ISSN: 0253-9624


  4 in total

1.  [Trend analysis of influenza vaccination among hospitalized elderly people in Beijing, 2013-2019].

Authors:  G Q Liu; Y J Pang; J Wu; M Lv; M K Yu; Y T Li; Y M Huang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-06-18

2.  Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals.

Authors:  Yanmei Liu; Sylvie Retout; Vincent Duval; Jingying Jia; Yang Zou; Yijun Wang; Valérie Cosson; Sébastien Jolivet; Stefan De Buck
Journal:  Clin Transl Sci       Date:  2022-02-19       Impact factor: 4.438

3.  Infectious diseases among elderly persons: Results from a population-based observational study in Shandong province, China, 2013-2017.

Authors:  Wan-Yu Du; Chao-Nan Yin; Hai-Tao Wang; Zhen-Wei Li; Wen-Jing Wang; Fu-Zhong Xue; Lin Zhao; Wu-Chun Cao
Journal:  J Glob Health       Date:  2021-12-25       Impact factor: 4.413

4.  Economic and health impacts of infectious diseases in China: A protocol for systematic review and meta analysis.

Authors:  Meiyue Li; Danxue Fan; Xiaowen Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.